Discover undervalued stocks with Eulerpool.

Subscribe for $2

MaxCyte Stock MXCT

Price

0.02
Today +/-
-0.00
Today %
-4.27 %

MaxCyte stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MaxCyte stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MaxCyte stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MaxCyte stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MaxCyte's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MaxCyte Stock Price History

DateMaxCyte Price
9/24/20250.02 undefined
9/24/20250.02 undefined
9/23/20250.02 undefined
9/20/20250.02 undefined
9/20/20250.02 undefined
9/19/20250.02 undefined
9/18/20250.02 undefined
9/17/20250.02 undefined
9/16/20250.02 undefined
9/13/20250.02 undefined
9/12/20250.02 undefined
9/11/20250.02 undefined
9/10/20250.02 undefined
9/9/20250.02 undefined
9/6/20250.02 undefined
9/5/20250.02 undefined
9/4/20250.02 undefined
9/3/20250.02 undefined
8/30/20250.02 undefined
8/29/20250.02 undefined
8/28/20250.02 undefined

MaxCyte Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MaxCyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MaxCyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MaxCyte’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MaxCyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MaxCyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MaxCyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MaxCyte’s growth potential.

MaxCyte Revenue, EBIT and net profit per share

DateMaxCyte RevenueMaxCyte EBITMaxCyte Net Income
2030e210.68 M undefined0 undefined0 undefined
2029e135.92 M undefined13.59 M undefined0 undefined
2028e84.95 M undefined-8.5 M undefined0 undefined
2027e52.19 M undefined-33.98 M undefined-41.71 M undefined
2026e42.62 M undefined-53.12 M undefined-45.45 M undefined
2025e37.13 M undefined-55.07 M undefined-45.27 M undefined
202438.63 M undefined-51.2 M undefined-41.06 M undefined
202341.29 M undefined-48.3 M undefined-37.92 M undefined
202244.26 M undefined-27.36 M undefined-23.57 M undefined
202133.89 M undefined-18.19 M undefined-19.08 M undefined
202026.17 M undefined-11.06 M undefined-11.82 M undefined
201921.62 M undefined-12.42 M undefined-12.9 M undefined
201816.67 M undefined-8.42 M undefined-8.87 M undefined
201713.99 M undefined-9.29 M undefined-9.92 M undefined
201612.27 M undefined-2.72 M undefined-3.85 M undefined
20159.29 M undefined-760,000 undefined-3.52 M undefined
20147.16 M undefined-1.28 M undefined-6.3 M undefined
20136.81 M undefined-800,000 undefined-2.86 M undefined
20125.06 M undefined-1.96 M undefined-3.89 M undefined

MaxCyte Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
567912131621263344413837425284135210
-20.0016.6728.5733.338.3323.0831.2523.8126.9233.33-6.82-7.32-2.6313.5123.8161.5460.7155.56
80.00100.0085.7188.8983.3392.3187.5090.4888.4690.9188.6487.8081.5883.7873.8159.6236.9022.9614.76
4668101214192330393631000000
-3-2-6-3-3-9-8-12-11-19-23-37-41-45-45-41000
--33.33200.00-50.00-200.00-11.1150.00-8.3372.7321.0560.8710.819.76--8.89---
43.4743.4743.4743.4733.5248.6451.1856.469.4690.62101.7103.27104.85000000
- - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The MaxCyte Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MaxCyte is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2012201320142015201620172018201920202021202220232024
                         
1.40.83.42.411.725.314.416.734.8255227.3168.29154.48
0.60.81.41.52.43.24.93.25.26.913.65.784.68
0000000000000
0.50.70.91.11.31.32.23.74.35.28.612.238.91
0.10.10.31.20.30.70.90.813.32.87.83.61
2.62.466.215.730.522.424.445.3270.4252.3194.09171.68
0.20.20.20.20.30.81.85.56.513.433.634.7530.47
0000000000042.9435.78
0000000000000
0000000000000
0000000000000
0000000000.30.80.391.53
0.20.20.20.20.30.81.85.56.513.734.478.0867.79
2.82.66.26.41631.324.229.951.8284.1286.7272.17239.47
                         
30.832.343.745.30.40.50.50.60.8111.041.06
000056.480.782.396.4127.7376.2390.8406.93422.05
-31.4-33.9-45.4-48.4-51.7-61.6-70.5-83.4-95.2-114.3-137.9-175.8-216.85
0000000000000
0000000000000
-0.6-1.6-1.7-3.15.119.612.313.633.3262.9253.9232.17206.25
11.41.42.33.24.34.12.10.91.80.50.741.36
00000004.15.97.18.212.049.17
0.60.81.422.52.12.43.24.86.76.75.075.25
0000000000000
1.81.81.60.8000000000
3.444.45.15.76.46.59.411.615.615.417.8615.78
0.10.13.64.3555.14.94.90000
0000000000000
000.10.10.30.40.42.125.617.318.2517.44
0.10.13.74.45.35.45.576.95.617.318.2517.44
3.54.18.19.51111.81216.418.521.232.736.1133.22
2.92.56.46.416.131.424.33051.8284.1286.6268.27239.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MaxCyte provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MaxCyte's financial health and stability.

Assets

MaxCyte's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MaxCyte must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MaxCyte after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MaxCyte's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (k)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-10-1-1-3-9-8-12-11-19-23
00000000112
00000000000
0001,00000-3,0001,0000-1,000-3,000
0000012351621
00000000000
00000000000
-20-10-2-9-10-8-8-10-14
0000000-1-2-3-18
000000-30-16-195-24
000000-3,0001,000-14,000-191,000-6,000
00000000000
103000000-40
00101123012282392
10401123012282342
-----------
00000000000
0020913-143329-36
-2.15-0.61-2.08-0.27-2.56-10.29-11.2-10.07-10.85-14.51-33.26
00000000000

MaxCyte stock margins

The MaxCyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MaxCyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MaxCyte.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MaxCyte's sales revenue. A higher gross margin percentage indicates that the MaxCyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MaxCyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MaxCyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MaxCyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MaxCyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MaxCyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MaxCyte Margin History

MaxCyte Gross marginMaxCyte Profit marginMaxCyte EBIT marginMaxCyte Profit margin
2030e81.62 %0 %0 %
2029e81.62 %10 %0 %
2028e81.62 %-10 %0 %
2027e81.62 %-65.12 %-79.92 %
2026e81.62 %-124.63 %-106.64 %
2025e81.62 %-148.3 %-121.93 %
202481.62 %-132.54 %-106.29 %
202388.51 %-116.98 %-91.85 %
202288.48 %-61.82 %-53.25 %
202189.26 %-53.67 %-56.3 %
202089.42 %-42.26 %-45.17 %
201988.44 %-57.45 %-59.67 %
201888.96 %-50.51 %-53.21 %
201789.56 %-66.4 %-70.91 %
201689.32 %-22.17 %-31.38 %
201588.91 %-8.18 %-37.89 %
201486.73 %-17.88 %-87.99 %
201388.11 %-11.75 %-42 %
201283.6 %-38.74 %-76.88 %

MaxCyte Stock Sales Revenue, EBIT, Earnings per Share

The MaxCyte earnings per share therefore indicates how much revenue MaxCyte has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MaxCyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MaxCyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MaxCyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MaxCyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MaxCyte Revenue, EBIT and net profit per share

DateMaxCyte Sales per ShareMaxCyte EBIT per shareMaxCyte Earnings per Share
2030e2.01 undefined0 undefined0 undefined
2029e1.3 undefined0 undefined0 undefined
2028e0.81 undefined0 undefined0 undefined
2027e0.5 undefined0 undefined-0.4 undefined
2026e0.41 undefined0 undefined-0.43 undefined
2025e0.35 undefined0 undefined-0.43 undefined
20240.37 undefined-0.49 undefined-0.39 undefined
20230.4 undefined-0.47 undefined-0.37 undefined
20220.44 undefined-0.27 undefined-0.23 undefined
20210.37 undefined-0.2 undefined-0.21 undefined
20200.38 undefined-0.16 undefined-0.17 undefined
20190.38 undefined-0.22 undefined-0.23 undefined
20180.33 undefined-0.16 undefined-0.17 undefined
20170.29 undefined-0.19 undefined-0.2 undefined
20160.37 undefined-0.08 undefined-0.11 undefined
20150.21 undefined-0.02 undefined-0.08 undefined
20140.16 undefined-0.03 undefined-0.14 undefined
20130.16 undefined-0.02 undefined-0.07 undefined
20120.12 undefined-0.05 undefined-0.09 undefined

MaxCyte business model

MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.com.

MaxCyte SWOT Analysis

Strengths

MaxCyte Inc has a strong reputation in the biotechnology industry, known for its innovative cell transfection technology.

The company has a solid intellectual property portfolio, protecting its technology and giving it a competitive edge.

MaxCyte Inc has established strategic partnerships with leading pharmaceutical companies, allowing for collaborative research and development opportunities.

With a skilled and experienced workforce, MaxCyte Inc possesses the necessary expertise to drive its growth and success.

Weaknesses

MaxCyte Inc's operations heavily rely on a few key clients, creating a potential risk of loss if these clients reduce their business or terminate contracts.

The company may face challenges in penetrating new markets due to intense competition and regulatory hurdles in the biotechnology industry.

MaxCyte Inc's financial performance is not as strong as some of its competitors, potentially limiting its ability to invest in research and development.

Opportunities

The growing demand for cell-based therapies presents an excellent opportunity for MaxCyte Inc to expand its market presence and increase revenues.

The company can leverage its technology to target the gene editing market, which is experiencing significant growth and offers promising commercial potential.

MaxCyte Inc can explore partnerships with academic institutions and research organizations to tap into emerging scientific advancements and broaden its product offerings.

Threats

MaxCyte Inc faces the risk of new entrants in the cell transfection technology market, which may challenge its market share and competitive position.

Changes in government regulations or policies related to biotechnology and gene editing could impact the company's operations and hinder its growth prospects.

The global economic conditions and fluctuations in exchange rates pose a threat to MaxCyte Inc's international operations and revenue streams.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

MaxCyte Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MaxCyte historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

MaxCyte shares outstanding

The number of shares was MaxCyte in 2024 — This indicates how many shares 104.849 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MaxCyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MaxCyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MaxCyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MaxCyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for MaxCyte.

MaxCyte latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.11 -0.12  (-13.85 %)2025 Q2
3/31/2025-0.11 -0.1  (6.63 %)2025 Q1
12/31/2024-0.12 -0.1  (19.61 %)2024 Q4
9/30/2024-0.13 -0.11  (12.56 %)2024 Q3
6/30/2024-0.13 -0.09  (30.34 %)2024 Q2
3/31/2024-0.13 -0.09  (32.13 %)2024 Q1
12/31/2023-0.07 -0.05  (31.88 %)2023 Q4
9/30/2023-0.1 -0.11  (-5.77 %)2023 Q3
6/30/2023-0.1 -0.1  (-2.15 %)2023 Q2
3/31/2023-0.11 -0.11  (3.68 %)2023 Q1
1
2

Eulerpool ESG Scorecard© for the MaxCyte stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

42

👫 Social

72

🏛️ Governance

44

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MaxCyte shareholders

%
Name
Stocks
Change
Date
8.50219 % Cadian Capital Management LP8,914,476-1,113,2516/30/2025
7.82841 % BlackRock Institutional Trust Company, N.A.8,208,023793,6946/30/2025
6.29475 % Mirabella Financial Services LLP6,600,0002,900,0006/30/2025
5.34261 % The Vanguard Group, Inc.5,601,68036,0156/30/2025
4.81010 % Vitruvian Partners LLP5,043,35606/30/2025
4.03910 % Morgan Stanley & Co. LLC4,234,965795,3636/30/2025
3.21480 % Mudita Advisors LLP3,370,68942,2486/30/2025
3.10273 % River Global Investors LLP3,253,1921,190,63012/31/2024
2.56669 % Morgan Stanley Investment Management Inc. (US)2,691,150-859,7346/30/2025
2.36577 % Geode Capital Management, L.L.C.2,480,488-100,5176/30/2025
1
2
3
4
5
...
10

MaxCyte Executives and Management Board

Mr. Douglas Swirsky

(54)
MaxCyte Chief Financial Officer
Compensation 1.19 M

Mr. Maher Masoud

(49)
MaxCyte President, Chief Executive Officer, Director (since 2020)
Compensation 890,365

Ms. Rekha Hemrajani

(55)
MaxCyte Non-Executive Independent Director
Compensation 243,027

Dr. Yasir Al-Wakeel

(42)
MaxCyte Non-Executive Independent Director
Compensation 238,527

Dr. Richard Douglas

(71)
MaxCyte Non-Executive Independent Chairman of the Board
Compensation 190,494
1
2
3

Most common questions regarding MaxCyte

What values and corporate philosophy does MaxCyte represent?

MaxCyte Inc represents a strong commitment to innovation and scientific excellence. The company values include providing cutting-edge cell engineering solutions and transformative technology for the advancement of healthcare and biotechnology. MaxCyte Inc's corporate philosophy focuses on delivering high-quality products and services, fostering collaboration among researchers, and driving advancements in cell-based therapies and drug discovery. By prioritizing customer satisfaction and continuous improvement, MaxCyte Inc aims to contribute to the progress of life sciences industry.

In which countries and regions is MaxCyte primarily present?

MaxCyte Inc is primarily present in the United States, as it is a Maryland-based biotechnology company. However, the company also has a global presence, with operations and collaborations in various countries and regions worldwide. Some notable regions where MaxCyte Inc has a presence include Europe, Asia-Pacific, and the Middle East. With its versatile cell engineering platform, MaxCyte Inc continues to expand its reach and partnerships internationally, catering to the demands of the biotech industry globally while focusing on its headquarters in the United States.

What significant milestones has the company MaxCyte achieved?

MaxCyte Inc has achieved significant milestones in its journey. The company has made remarkable advancements in the field of cell engineering and cutting-edge cell-based therapies. MaxCyte's proprietary technology, Flow Electroporation™, has revolutionized the delivery of nucleic acids, proteins, and cell-based therapeutics. The company has successfully developed a broad range of partnerships and collaborations with renowned pharmaceutical and biotechnology companies worldwide. MaxCyte has also received numerous grants and awards recognizing its contributions to the field. Through continuous innovation and strategic collaborations, MaxCyte Inc continues to strengthen its position as a leading player in the biotechnology industry.

What is the history and background of the company MaxCyte?

MaxCyte Inc is a renowned biotechnology company specializing in cell engineering and drug discovery. Founded in 1999, MaxCyte has established a strong presence in the life sciences industry. The company's innovative cell engineering platform, known as Flow Electroporation™ Technology, enables precise genetic modification of cells for various applications, including cell-based therapies, gene editing, and biomanufacturing. With a global customer base and strategic partnerships, MaxCyte continues to advance its technology and contribute to groundbreaking research in the field of biotechnology. MaxCyte Inc has emerged as a key player in shaping the future of personalized medicine and regenerative therapies.

Who are the main competitors of MaxCyte in the market?

The main competitors of MaxCyte Inc in the market include companies such as Thermo Fisher Scientific, Lonza Group, and Mirus Bio LLC. Thermo Fisher Scientific, a leading life sciences company, offers a range of products and services that overlap with MaxCyte Inc's transfection technology. Lonza Group, a multinational company, also provides cell and gene therapy solutions that compete with MaxCyte Inc's offerings. Mirus Bio LLC, a biotechnology company, focuses on developing innovative transfection reagents, making them a direct competitor in this space.

In which industries is MaxCyte primarily active?

MaxCyte Inc is primarily active in the biotechnology industry.

What is the business model of MaxCyte?

MaxCyte Inc is a biotechnology company specializing in cell-based therapies and life sciences. Their business model revolves around providing innovative solutions for cell engineering and drug development. MaxCyte's proprietary technology enables the efficient delivery of molecules into cells, ensuring targeted genetic modification and enhanced therapeutic efficacy. With a focus on collaborations and licensing agreements, MaxCyte aims to expand its reach across various therapeutic areas, including cancer, vaccines, gene editing, and regenerative medicine. By leveraging their expertise in high-performance cell engineering, MaxCyte Inc strives to revolutionize the field of medicine and contribute to the development of novel treatments.

What is the P/E ratio of MaxCyte 2025?

The MaxCyte P/E ratio is -0.05.

What is the P/S ratio of MaxCyte 2025?

The MaxCyte P/S ratio is 0.06.

What is the Quality Investing of MaxCyte?

The Quality Investing for MaxCyte is 5/10.

What is the revenue of MaxCyte 2025?

The expected MaxCyte revenue is 37.13 M USD.

How high is the profit of MaxCyte 2025?

The expected MaxCyte profit is -45.27 M USD.

What is the business model of MaxCyte

MaxCyte Inc is an emerging biotechnology company specializing in the development of platform technologies for the rapid and efficient production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to companies in the biotech and pharma industries. The company offers a versatile technology platform for the production of high-quality products with higher throughput and shorter production times. MaxCyte has developed a proprietary technology called electroporation, which allows for the direct transfer of DNA, RNA, proteins, and other molecules into cells. The company offers customers the opportunity to utilize this technology through licensing agreements to manufacture their own products or develop new therapeutic candidates. MaxCyte is divided into two business segments: Services and Products. The Services segment offers a range of customized services, from product development to the manufacture of clinical compounds. The Products segment includes various products based on the electroporation-based technology platform. MaxCyte also has partnerships with several major pharmaceutical and biotechnology companies to integrate its technology platform into the development and production of new product candidates. Overall, MaxCyte's business model focuses on the development and marketing of effective and efficient platform technologies for the production of therapeutics and vaccines. The company has established a strong network that includes both biotech and pharmaceutical companies. As the demand for state-of-the-art production technologies continues to grow, MaxCyte will play an important role in this field. Answer: MaxCyte Inc is a biotechnology company specializing in the development of platform technologies for the production of therapeutics and vaccines. Its business model is based on selling licenses and providing services to biotech and pharma companies. MaxCyte has a proprietary electroporation technology for transferring molecules into cells. They offer customized services and products based on this technology. The company also has partnerships with major pharma and biotech firms. Overall, MaxCyte aims to develop and market efficient production technologies for therapeutics and vaccines.

What is the MaxCyte dividend?

MaxCyte pays a dividend of 0 USD distributed over payouts per year.

How often does MaxCyte pay dividends?

The dividend cannot currently be calculated for MaxCyte or the company does not pay out a dividend.

What is the MaxCyte ISIN?

The ISIN of MaxCyte is US57777K1060.

What is the MaxCyte WKN?

The WKN of MaxCyte is A2AGVE.

What is the MaxCyte ticker?

The ticker of MaxCyte is MXCT.

How much dividend does MaxCyte pay?

Over the past 12 months, MaxCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MaxCyte is expected to pay a dividend of 0 USD.

What is the dividend yield of MaxCyte?

The current dividend yield of MaxCyte is .

When does MaxCyte pay dividends?

MaxCyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MaxCyte?

MaxCyte paid dividends every year for the past 0 years.

What is the dividend of MaxCyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MaxCyte located?

MaxCyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von MaxCyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MaxCyte from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did MaxCyte pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of MaxCyte in the year 2024?

In the year 2024, MaxCyte distributed 0 USD as dividends.

In which currency does MaxCyte pay out the dividend?

The dividends of MaxCyte are distributed in USD.

All fundamentals about MaxCyte

Our stock analysis for MaxCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MaxCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.